Vertex Pharmaceuticals Inc (VRTX)

05:49 AM

Vertex, Crispr’s Casgevy Accused of Infringing New ToolGen Patent - Bloomberg Law News

05:49 AM

04:00 AM

Vertex to Participate in the Citi’s 2025 Global Healthcare Conference on December 3 - Business Wire

04:00 AM

07:54 AM

How risky is Vertex Pharmaceuticals Incorporated (VX1) stock compared to peersQuarterly Performance Summary & Fast Entry and Exit Trade Plans - newser.com

07:54 AM

04:40 AM

Is Vertex Pharmaceuticals Incorporated (VX1) stock a buy on weakness - newser.com

04:40 AM

12:35 PM

How Vertex Pharmaceuticals Incorporated (VX1) stock moves on employment dataIPO Watch & Target Return Focused Picks - newser.com

12:35 PM

Nov 18, 2025

Will Vertex Pharmaceuticals Incorporated benefit from macro trendsTrade Volume Report & Reliable Intraday Trade Alerts - newser.com

Nov 18, 2025

Nov 18, 2025

Exit strategy if you’re trapped in Vertex Pharmaceuticals Incorporated2025 Sector Review & Risk Adjusted Buy/Sell Alerts - newser.com

Nov 18, 2025

Nov 18, 2025

Is Vertex Pharmaceuticals Incorporated stock a smart buy before Fed meetingPortfolio Gains Report & Technical Confirmation Trade Alerts - newser.com

Nov 18, 2025

Nov 18, 2025

A Look at Vertex Pharmaceuticals’s Valuation Following Promising Kidney Trial Updates and New FDA Designations - Yahoo Finance

Nov 18, 2025

Nov 18, 2025

Vertex Pharmaceuticals Stock: Analyst Estimates & Ratings - MSN

Nov 18, 2025

Nov 18, 2025

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Nov 18, 2025

Nov 18, 2025

Vertex Pharmaceuticals Incorporated’s volatility index tracking explainedMarket Trend Review & Advanced Swing Trade Entry Alerts - newser.com

Nov 18, 2025

Nov 18, 2025

Stifel Maintains Hold Rating on Vertex (VRTX), Keeps $445 Price Target - Insider Monkey

Nov 18, 2025

Nov 17, 2025

Published on: 2025-11-17 18:09:39 - newser.com

Nov 17, 2025

Nov 17, 2025

Vertex Pharmaceuticals Insider Sold Shares Worth $32,292,320, According to a Recent SEC Filing - MarketScreener

Nov 17, 2025

Nov 17, 2025

Is Vertex Pharmaceuticals Inc Gaining or Losing Market Support? - Benzinga

Nov 17, 2025

Nov 17, 2025

Published on: 2025-11-17 12:00:44 - newser.com

Nov 17, 2025

Nov 17, 2025

1 Incredible Reason to Buy Vertex Pharmaceuticals Stock in November - Finviz

Nov 17, 2025

Nov 16, 2025

Visual analytics tools that track Vertex Pharmaceuticals Incorporated performanceJuly 2025 Opening Moves & Technical Buy Zone Confirmations - newser.com

Nov 16, 2025

Nov 16, 2025

My 3 Favorite Stocks to Buy Right Now - Finviz

Nov 16, 2025

Nov 16, 2025

My 3 Favorite Stocks to Buy Right Now - The Motley Fool

Nov 16, 2025

Nov 16, 2025

Published on: 2025-11-16 04:54:52 - newser.com

Nov 16, 2025

Nov 14, 2025

Daiwa Securities Adjusts Price Target on Vertex Pharmaceuticals to $500 From $430, Maintains Buy Rating - MarketScreener

Nov 14, 2025

Nov 13, 2025

Evercore ISI Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail

Nov 13, 2025

Nov 12, 2025

Novartis, Vertex, More Optimizing Shots on Multiple Goals in Lucrative I&I Space - BioSpace

Nov 12, 2025

Nov 12, 2025

Vertex Pharmaceuticals’ Promising Cystic Fibrosis Study: A Potential Game-Changer - MSN

Nov 12, 2025

Nov 11, 2025

Vertex highlights growing Medicaid coverage for non-opioid painkiller Journavx (VRTX:NASDAQ) - Seeking Alpha

Nov 11, 2025

Nov 11, 2025

Transcript : Vertex Pharmaceuticals Incorporated Presents at UBS Global Healthcare Conference 2025, Nov-09-2025 through Nov-12-2025 - MarketScreener

Nov 11, 2025

Nov 11, 2025

Barclays Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX) - The Globe and Mail

Nov 11, 2025

Nov 10, 2025

The Bull Case for Vertex Pharmaceuticals (VRTX) Could Change Following Strong Kidney Data and Regulatory Progress - Yahoo Finance

Nov 10, 2025

Nov 10, 2025

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Alnylam Pharma (ALNY) and Insulet (PODD) - The Globe and Mail

Nov 10, 2025

Nov 10, 2025

Vertex Pharmaceuticals: Promising Growth in Renal Disease Market with Strong Clinical Data and Strategic Development - TipRanks

Nov 10, 2025

Nov 10, 2025

Vertex stock holds steady as Stifel maintains $445 price target By Investing.com - Investing.com UK

Nov 10, 2025

Nov 10, 2025

Vertex Pharmaceuticals’ Promising Renal Franchise Developments Justify Buy Rating - TipRanks

Nov 10, 2025